When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in November, the British biotech sounded confident that the latest readout set them up for a phase 3 trial. But by the sound of Silence’s latest update, those phase 3 plans have been tuned out at the same time as the company adjusts to losing out on up to $1.3 billion in potential biobucks from a collaboration with Hansoh Pharma who “opted not to pursue further development". Source: Fierce Biotech 27/2/2025